INBX

Inhibrx Biosciences' stock has experienced significant movements driven by clinical updates and financial news. The stock price saw a substantial increase of 944.53% between May 5, 2025, and May 1, 2026. In March 2026, Inhibrx reported its Fourth Quarter and Fiscal Year 2025 financial results, showing a net loss of $140.1 million for FY25, and announced plans to submit a BLA for ozekibart and interim ORR data for INBRX-106. In April 2026, the stock experienced notable positive movement, including a 7.61% gain as of April 24, 2026, and a significant increase of 36.88% on April 22, 2026. News emerged that cancer therapies from Inhibrx were reportedly drawing big pharma interest, and the stock hit record highs. The stock was up 46.3% following new ozekibart colorectal cancer data and FDA plans. In December 2025, Citizens reiterated a "Market Perform" rating on INBX stock, citing concerns about limited data disclosures and a lack of management communication. Inhibrx secured an additional $75 million in financing through an amended loan agreement to strengthen its financial position in March 2026.